StockWatch
·
Q2 FY-2027 RESULTS · PAJSON

Pajson Agro H1 FY27: PAT down 12% YoY on margin compression despite 21% revenue growth

PAT -11.65% YoY · revenue +21.14% · margins compressing

Q2 FY27 resultsPAJSONPajson Agro India Ltd02 Nov 2026 · 3 min read
Revenue

₹143.39 Cr

+21.14% YoY

PAT (standalone)

₹12.56 Cr

-11.65% YoY

Net margin

8.66%

EPS

₹5.27

Pajson Agro's standalone H1 FY27 revenue from operations rose 21.1% YoY to ₹143.39 Cr (from ₹118.37 Cr in H1 FY26), but PAT fell 11.6% YoY to ₹12.56 Cr (from ₹14.21 Cr) as EBITDA margin compressed to roughly 14.2% from roughly 17.8% a year earlier. Sequentially the picture is better — PAT rose 18.8% QoQ from H2 FY26's ₹10.57 Cr and EBITDA margin improved from roughly 12.2% — but per the YoY-primary read, profitability lagged revenue growth this half.

The scoreboard

Q2 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹143.39 Cr——
Expenses₹128.2 Cr——
PAT₹12.56 Cr+18.76%-11.65%
Net margin8.66%——
EPS₹5.27——

No year-ago quarter on record — YoY cells may be blank.

The squeeze sits on two lines: the raw-material cost ratio (cost of materials consumed/revenue) rose to 83.1% from 81.2% YoY, and finance costs more than doubled to ₹2.26 Cr from ₹1.07 Cr as short-term borrowings nearly doubled to ₹59.25 Cr (from ₹34.06 Cr at FY26-end) to fund a large inventory build (₹95.69 Cr from ₹37.59 Cr) and ongoing capex. Capital work-in-progress jumped to ₹16.37 Cr from ₹0.33 Cr, consistent with construction of the Greenfield facility; none of that capacity is yet contributing to revenue.

₹
154.68220.34286351.66417.3227007-3008-2109-1510-0811-02Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹270, up 27.4% over the past month of trading.

Beyond the headline

What the summary numbers don't show

EPS (not annualised) ₹5.27 for H1 FY27 vs ₹8.12 in H1 FY26.

What management guided (4 FY-2026 call)
Management guides for approximately 20% revenue growth from existing operations in FY27, with the new Greenfield facility beginning commercial production in Q4. They project a recovery in EBITDA margins to a steady state of 15-16%, supported by forex hedging and operational efficiencies. The long-term strategy is cente

— This quarter: missed

Management's FY26 Q4 concall had guided to roughly 20% FY27 revenue growth from existing operations — H1's +21.1% YoY is in line to slightly ahead — and to EBITDA margin recovering to a 15-16% steady state aided by forex hedging and operational efficiencies. The 14.2% margin posted is still short of that band, though it is recovering sequentially from H2 FY26's 12.2%, so the print tracks the guided direction without yet reaching the target. No management press release accompanied this filing to cross-check that framing. As a BSE SME-platform microcap (₹23.81 Cr paid-up capital, listed December 2025 at a ₹108/share premium) it carries no visible analyst coverage, so vsStreet is unknown rather than estimated. Concurrently, the company disclosed a board meeting on November 4 to consider securities issuance and an ESOP, and had utilised ₹35.64 Cr of its ₹74.45 Cr IPO proceeds by period-end, including ₹18.27 Cr of the ₹57 Cr earmarked for the new manufacturing unit.

  • W1

    Whether EBITDA margin reaches management's guided 15-16% steady state — H1 FY27 came in at ~14.2%, still short of that band.

  • W2

    Commercial production start at the new Greenfield facility, guided for Q4 — CWIP at ₹16.37 Cr signals construction underway but no output yet.

  • W3

    Short-term borrowings (₹59.25 Cr, up from ₹34.06 Cr) and finance cost trajectory as the facility nears completion and working capital needs evolve.

Pajson Agro is BSE SME-listed and files half-yearly, not quarterly — these are cumulative H1 FY27 (Apr-Sep 2026) standalone figures, not a discrete Q2; no exceptional items in either period; result is unaudited (limited review only); no consolidated statement exists.

Informational and educational content only. Not investment advice.